Bristol Myers Squibb To Present New Findings on CAMZYOS, ELIQUIS, and Milvexian Cardiovascular Treatments at ESC Congress

Author: Benzinga Newsdesk | August 26, 2024 07:01am

Bristol Myers Squibb (NYSE:BMY) today announced the presentation of research across its robust cardiovascular portfolio at the European Society of Cardiology(ESC) Congress, taking place August 30 – September 2, 2024, in London, England. Data to be presented at the meeting includes long-term extension data evaluating the efficacy and safety profile of CAMZYOS® (mavacamten) up to 180 weeks (3.5 years) for the treatment of New York Heart Association (NYHA) class II-III symptomatic obstructive hypertrophic cardiomyopathy (oHCM), as well as data on behalf of the BMS-Pfizer Alliance on ELIQUIS® (apixaban) and the BMS-Johnson & Johnson Collaboration on milvexian.

Posted In: BMY